Carboplatin plus paclitaxel improves quality of life in ovarian cancer
the ONA take:
There is no significant quality of life advantage of cisplatin plus topotecan compared with paclitaxel plus carboplatin in the treatment of women with newly diagnosed ovarian cancer, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
A recent phase 3 study in women with newly diagnosed stage 2B or greater ovarian cancer found that cisplatin plus topotecan followed by carboplatin plus paclitaxel had a significantly lower response rate vs paclitaxel plus carboplatin. The study also demonstrated no significant difference in progression-free survival at 43 months of follow-up.
In this analysis, researchers sought to evaluate the impact of each regimen on quality of life. Results showed that global quality of life, physical symptoms, fatigue, and various function scores significantly improved in both groups, but there was no significant difference between the arms. Researchers found that nausea and vomiting improve more with paclitaxel plus carboplatin during and after treatment.
The findings of this analysis combined with the efficacy results of the phase 3 trial suggest that carboplatin plus paclitaxel should continue to be the standard of care for patients with newly diagnosed ovarian cancer.
There is no significant quality of life advantage of cisplatin plus topotecan in treatment of women with newly diagnosed ovarian cancer.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|